Global Chagas Disease Drug Market Research Report 2019
Table of Contents
Executive Summary
1 Chagas Disease Drug Market Overview
- 1.1 Product Overview and Scope of Chagas Disease Drug
- 1.2 Chagas Disease Drug Segment by Type
- 1.2.1 Global Chagas Disease Drug Production Growth Rate Comparison by Type (2014-2025)
- 1.2.2 Cz-007
- 1.2.3 Cz-008
- 1.2.4 D-121
- 1.2.5 DNDI-0690
- 1.2.6 EPLBS-1246
- 1.2.7 EPLBS-967
- 1.2.8 Others
- 1.3 Chagas Disease Drug Segment by Application
- 1.3.1 Chagas Disease Drug Consumption Comparison by Application (2014-2025)
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Others
- 1.3 Global Chagas Disease Drug Market by Region
- 1.3.1 Global Chagas Disease Drug Market Size Region
- 1.3.2 North America Status and Prospect (2014-2025)
- 1.3.3 Europe Status and Prospect (2014-2025)
- 1.3.4 China Status and Prospect (2014-2025)
- 1.3.5 Japan Status and Prospect (2014-2025)
- 1.3.6 Southeast Asia Status and Prospect (2014-2025)
- 1.3.7 India Status and Prospect (2014-2025)
- 1.4 Global Chagas Disease Drug Market Size
- 1.4.1 Global Chagas Disease Drug Revenue (2014-2025)
- 1.4.2 Global Chagas Disease Drug Production (2014-2025)
2 Global Chagas Disease Drug Market Competition by Manufacturers
- 2.1 Global Chagas Disease Drug Production Market Share by Manufacturers (2014-2019)
- 2.2 Global Chagas Disease Drug Revenue Share by Manufacturers (2014-2019)
- 2.3 Global Chagas Disease Drug Average Price by Manufacturers (2014-2019)
- 2.4 Manufacturers Chagas Disease Drug Production Sites, Area Served, Product Types
- 2.5 Chagas Disease Drug Market Competitive Situation and Trends
- 2.5.1 Chagas Disease Drug Market Concentration Rate
- 2.5.2 Chagas Disease Drug Market Share of Top 3 and Top 5 Manufacturers
- 2.5.3 Mergers & Acquisitions, Expansion
3 Global Chagas Disease Drug Production Market Share by Regions
- 3.1 Global Chagas Disease Drug Production Market Share by Regions
- 3.2 Global Chagas Disease Drug Revenue Market Share by Regions (2014-2019)
- 3.3 Global Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 3.4 North America Chagas Disease Drug Production
- 3.4.1 North America Chagas Disease Drug Production Growth Rate (2014-2019)
- 3.4.2 North America Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 3.5 Europe Chagas Disease Drug Production
- 3.5.1 Europe Chagas Disease Drug Production Growth Rate (2014-2019)
- 3.5.2 Europe Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 3.6 China Chagas Disease Drug Production (2014-2019)
- 3.6.1 China Chagas Disease Drug Production Growth Rate (2014-2019)
- 3.6.2 China Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 3.7 Japan Chagas Disease Drug Production (2014-2019)
- 3.7.1 Japan Chagas Disease Drug Production Growth Rate (2014-2019)
- 3.7.2 Japan Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
4 Global Chagas Disease Drug Consumption by Regions
- 4.1 Global Chagas Disease Drug Consumption by Regions
- 4.2 North America Chagas Disease Drug Consumption (2014-2019)
- 4.3 Europe Chagas Disease Drug Consumption (2014-2019)
- 4.4 China Chagas Disease Drug Consumption (2014-2019)
- 4.5 Japan Chagas Disease Drug Consumption (2014-2019)
5 Global Chagas Disease Drug Production, Revenue, Price Trend by Type
- 5.1 Global Chagas Disease Drug Production Market Share by Type (2014-2019)
- 5.2 Global Chagas Disease Drug Revenue Market Share by Type (2014-2019)
- 5.3 Global Chagas Disease Drug Price by Type (2014-2019)
- 5.4 Global Chagas Disease Drug Production Growth by Type (2014-2019)
6 Global Chagas Disease Drug Market Analysis by Applications
- 6.1 Global Chagas Disease Drug Consumption Market Share by Application (2014-2019)
- 6.2 Global Chagas Disease Drug Consumption Growth Rate by Application (2014-2019)
7 Company Profiles and Key Figures in Chagas Disease Drug Business
- 7.1 AstraZeneca Plc
- 7.1.1 AstraZeneca Plc Chagas Disease Drug Production Sites and Area Served
- 7.1.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.1.3 AstraZeneca Plc Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.1.4 Main Business and Markets Served
- 7.2 Bayer AG
- 7.2.1 Bayer AG Chagas Disease Drug Production Sites and Area Served
- 7.2.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.2.3 Bayer AG Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.2.4 Main Business and Markets Served
- 7.3 Daiichi Sankyo Co Ltd
- 7.3.1 Daiichi Sankyo Co Ltd Chagas Disease Drug Production Sites and Area Served
- 7.3.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.3.3 Daiichi Sankyo Co Ltd Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.3.4 Main Business and Markets Served
- 7.4 Eisai Co Ltd
- 7.4.1 Eisai Co Ltd Chagas Disease Drug Production Sites and Area Served
- 7.4.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.4.3 Eisai Co Ltd Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.4.4 Main Business and Markets Served
- 7.5 GlaxoSmithKline Plc
- 7.5.1 GlaxoSmithKline Plc Chagas Disease Drug Production Sites and Area Served
- 7.5.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.5.3 GlaxoSmithKline Plc Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.5.4 Main Business and Markets Served
- 7.6 Grupo Praxis Pharmaceutical SA
- 7.6.1 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Production Sites and Area Served
- 7.6.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.6.3 Grupo Praxis Pharmaceutical SA Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.6.4 Main Business and Markets Served
- 7.7 Humanigen Inc
- 7.7.1 Humanigen Inc Chagas Disease Drug Production Sites and Area Served
- 7.7.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.7.3 Humanigen Inc Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.7.4 Main Business and Markets Served
- 7.8 Kancera AB
- 7.8.1 Kancera AB Chagas Disease Drug Production Sites and Area Served
- 7.8.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.8.3 Kancera AB Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.8.4 Main Business and Markets Served
- 7.9 Merck & Co Inc
- 7.9.1 Merck & Co Inc Chagas Disease Drug Production Sites and Area Served
- 7.9.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.9.3 Merck & Co Inc Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.9.4 Main Business and Markets Served
- 7.10 Novartis AG
- 7.10.1 Novartis AG Chagas Disease Drug Production Sites and Area Served
- 7.10.2 Chagas Disease Drug Product Introduction, Application and Specification
- 7.10.3 Novartis AG Chagas Disease Drug Production, Revenue, Price and Gross Margin (2014-2019)
- 7.10.4 Main Business and Markets Served
- 7.11 Oblita Therapeutics BVBA
- 7.12 Sanofi
8 Chagas Disease Drug Manufacturing Cost Analysis
- 8.1 Chagas Disease Drug Key Raw Materials Analysis
- 8.1.1 Key Raw Materials
- 8.1.2 Price Trend of Key Raw Materials
- 8.1.3 Key Suppliers of Raw Materials
- 8.2 Proportion of Manufacturing Cost Structure
- 8.3 Manufacturing Process Analysis of Chagas Disease Drug
- 8.4 Chagas Disease Drug Industrial Chain Analysis
9 Marketing Channel, Distributors and Customers
- 9.1 Marketing Channel
- 9.1.1 Direct Marketing
- 9.1.2 Indirect Marketing
- 9.2 Chagas Disease Drug Distributors List
- 9.3 Chagas Disease Drug Customers
10 Market Dynamics
- 10.1 Market Trends
- 10.2 Opportunities
- 10.3 Market Drivers
- 10.4 Challenges
- 10.5 Influence Factors
11 Global Chagas Disease Drug Market Forecast
- 11.1 Global Chagas Disease Drug Production, Revenue Forecast
- 11.1.1 Global Chagas Disease Drug Production Growth Rate Forecast (2019-2025)
- 11.1.2 Global Chagas Disease Drug Revenue and Growth Rate Forecast (2019-2025)
- 11.1.3 Global Chagas Disease Drug Price and Trend Forecast (2019-2025)
- 11.2 Global Chagas Disease Drug Production Forecast by Regions (2019-2025)
- 11.2.1 North America Chagas Disease Drug Production, Revenue Forecast (2019-2025)
- 11.2.2 Europe Chagas Disease Drug Production, Revenue Forecast (2019-2025)
- 11.2.3 China Chagas Disease Drug Production, Revenue Forecast (2019-2025)
- 11.2.4 Japan Chagas Disease Drug Production, Revenue Forecast (2019-2025)
- 11.3 Global Chagas Disease Drug Consumption Forecast by Regions (2019-2025)
- 11.3.1 North America Chagas Disease Drug Consumption Forecast (2019-2025)
- 11.3.2 Europe Chagas Disease Drug Consumption Forecast (2019-2025)
- 11.3.3 China Chagas Disease Drug Consumption Forecast (2019-2025)
- 11.3.4 Japan Chagas Disease Drug Consumption Forecast (2019-2025)
- 11.4 Global Chagas Disease Drug Production, Revenue and Price Forecast by Type (2019-2025)
- 11.5 Global Chagas Disease Drug Consumption Forecast by Application (2019-2025)
12 Research Findings and Conclusion
13 Methodology and Data Source
- 13.1 Methodology/Research Approach
- 13.1.1 Research Programs/Design
- 13.1.2 Market Size Estimation
- 13.1.3 Market Breakdown and Data Triangulation
- 13.2 Data Source
- 13.2.1 Secondary Sources
- 13.2.2 Primary Sources
- 13.3 Author List
The global Chagas Disease Drug market is valued at million US$ in 2018 is expected to reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
This report focuses on Chagas Disease Drug volume and value at global level, regional level and company level. From a global perspective, this report represents overall Chagas Disease Drug market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan.
At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer covered in this report.
The following manufacturers are covered:
AstraZeneca Plc
Bayer AG
Daiichi Sankyo Co Ltd
Eisai Co Ltd
GlaxoSmithKline Plc
Grupo Praxis Pharmaceutical SA
Humanigen Inc
Kancera AB
Merck & Co Inc
Novartis AG
Oblita Therapeutics BVBA
Sanofi
Segment by Regions
North America
Europe
China
Japan
Segment by Type
Cz-007
Cz-008
D-121
DNDI-0690
EPLBS-1246
EPLBS-967
Others
Segment by Application
Hospital
Clinic
Others